Keros Therapeutics Inc (KROS)

Nov 11, 2026

Zacks Research has upgraded Keros Therapeutics (NASDAQ:KROS) to a "strong buy" rating, noting the company's strong quarterly performance where it significantly beat EPS and revenue estimates. The firm also authorized a $5 million share-repurchase plan. Despite an overall "Moderate Buy" consensus from analysts with an average price target of $21.40, Keros still faces some uncertainty regarding its path to profitability.

Nov 9, 2026

Keros Therapeutics (NASDAQ:KROS) has been upgraded from a "strong sell" to a "hold" rating by Wall Street Zen, aligning with the broader analyst consensus and an average price target of $21.40. The company recently reported strong quarterly earnings, significantly beating analyst estimates with $0.70 per share and revenue of $40.01 million. Keros Therapeutics also announced a $5 million share repurchase program, indicating management's belief that the stock is undervalued.

Nov 6, 2026

Keros Therapeutics (NASDAQ:KROS) reported strong quarterly earnings, beating analyst estimates with an EPS of $0.70 compared to an expected loss of $0.96, and revenue of $40.01 million against a forecast of $14.76 million. Despite the positive results, shares fell $1.38 to $9.45, nearing a 12-month low. The company's board also authorized a $5 million share buyback program.

Nov 5, 2026

Keros Therapeutics (KROS) reported Q3 earnings of $0.7 per share, significantly surpassing the Zacks Consensus Estimate of a loss of $0.96 per share, and revenues of $40.01 million, beating estimates by 197.47%. Despite these strong quarterly results, the company's shares have fallen 46.8% year-to-date, contrasting with the S&P 500's gain, and currently hold a Zacks Rank #3 (Hold). Investors are now looking to future earnings calls for management's commentary and estimate revisions to gauge the stock's future performance.

Nov 4, 2026

This article provides an in-depth analysis of Keros Therapeutics Inc. (NASDAQ: KROS), highlighting near-term weak sentiment that may signal a resumption of long-term weakness. It identifies a strong risk-reward short setup and outlines three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis for near-term, mid-term, and long-term horizons, indicating prevailing weak sentiment.

Nov 1, 2026

Wall Street Zen downgraded Keros Therapeutics (NASDAQ:KROS) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Hold" with a target price of $20.50. KROS shares opened at $11.04, near its 52-week low, after reporting a quarterly loss of $1.45 per share, missing consensus estimates. The company has also approved a $5 million stock buyback program, indicating management's belief that the stock may be undervalued.